PHARMA FAMOTIDINE TABLET 20mg

Product Information

Registration Status: Active

PHARMA FAMOTIDINE TABLET 20mg is approved to be sold in Singapore with effective from 1998-11-27. It is marketed by PHARMAFORTE SINGAPORE PTE LTD, with the registration number of SIN10470P.

This product contains Famotidine 20mg in the form of TABLET, FILM-COATED. It is approved for ORAL use.

This product is manufactured by KOREA PHARMA CO LTD in KOREA, and in REPUBLIC OF.

It is a has been granted the exemption for supply without a presciption if it met certain criteria.

Reclassified Info

Famotidine

Description

A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. [PubChem]

Indication

For the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD).

Mechanism of Action

Famotidine binds competitively to H2-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin.

Pharmacokinetics

Absorption
The bioavailability of oral doses is 40-45%.
Distribution
Metabolism
Hepatic.
Elimination

Clearance

* renal cl=250-450 mL/min

Toxicity

Intravenous, mouse: LD50 = 244.4mg/kg; Oral, mouse: LD50 = 4686 mg/kg. Symptoms of overdose include emesis, restlessness, pallor of mucous membranes or redness of mouth and ears, hypotension, tachycardia and collapse.

Active Ingredient/Synonyms

(1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide | 3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide | 3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine | Famotidina | Famotidinum | N-Sulfamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide | Famotidine |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank